Cost-Effective Interventions

Interventions are actions taken by or for individuals to reduce the risk, duration, or severity of adverse health conditions. Interventions may be population-based or personal.

DCP2 and GBD present what we know about which health interventions work for a comprehensive range of diseases, injuries, and disabilities in many different contexts. A large share of the disease burden in low- and middle-income countries is attributable to diseases and conditions for which cost-effective interventions are already known and feasible. Selecting the right intervention for a given disease and context matters a great deal. The tools on this page are designed to aid the task.

DCP2 and GBD demonstrate how decision makers could use cost-effectiveness information in combination with information on disease prevalence and avertable illness to determine which interventions should be extended and which ones should be questioned. If developing countries scale up interventions and extend health care services that are cost-effective, the impact on the disease burden could be substantial.

Select Criteria

Disease / Condition Setting Type Objective Target population

Download Results (CSV)  |  Download Full Data Set (XLS)

Condition Intervention Intervention type Intervention description Intervention setting Objective Target population Cost effectiveness (US$/DALY) Cost effectiveness estimate (US$) Cost effectiveness range (US$/DALY) Number of DALYs averted (hundreds) Number of deaths averted (hundreds) Quality of cost-effectiveness analysis evidence
Cervical cancer Chemoradiation therapy Personal Cisplatin-based chemoradiation regimens on the basis of published and estimated survival. Local or district hospital secondary prevention Adults, Women of childbearing age, Adolescents and adults - 337-31,400 per LYS (USA) - - - 1
Cervical cancer Conventional or liquidbased cytology testing Personal Conventional cytology using the Papanicolaou (Pap) smear and HPV testing every 1 to 10 years; or Liquid-based cytology using the Papanicolaou (Pap) smear and HPV testing every 1 to 5 years Local or district hospital secondary prevention Adults, Women of childbearing age, Adolescents and adults - 126,500 (USA); 162,400 (Thailand) - - - 2
Cervical cancer Nationwide Pap screening program based on fiveyear intervals Personal Nationwide Pap screening program based on five-year intervals Local or district hospital secondary prevention Adults, Women of childbearing age, Adolescents and adults - 769 per YLS (Vietnam) - - - 2
Cervical cancer One-visit VIA Personal Cervix is viewed after the application of an acetic acid solution; screening and treatment conducted during the same visit Local or district hospital secondary prevention Adults, Women of childbearing age, Adolescents and adults - 56 per YLS (Brazil); 54 per YLS (Madagascar); 43 per YLS (Zimbabwe) - - - 1
Cervical cancer Three-visit cytology Personal Cytology sample obtained during the first visit, colposcopy for screen-positive women conducted during the second visit, and treatment provided during the third visit Local or district hospital secondary prevention Adults - 589 per YLS (Brazil); 379 per YLS (Madagascar); 331 per YLS (Zimbabwe) - - - 1
Cervical cancer Two-visit HPV testing Personal HPV DNA testing during the first visit followed by treatment of screen-positive women during the second visit Local or district hospital secondary prevention Adults, Women of childbearing age, Adolescents and adults - 122 per YLS (Brazil); 167 per YLS (Madagascar); 41 per YLS (South Africa); 117 per YLS (Zimbabwe) - - - 1

Download Results (CSV)  |  Download Full Data Set (XLS)